Mucosis

About:

Mucosis is a clinical stage Dutch biotechnology company developing mucosal vaccines.

Website: http://www.mucosis.com

Twitter/X: mucosis

Top Investors: Wellcome Trust, BioGeneration Ventures, NV NOM, Utrecht Holdings, Changchun BCHT Biotechnology

Description:

Mucosis B.V. is a clinical stage Dutch biotechnology company developing innovative mucosal vaccines that can be applied needle-free via the nose or mouth. Mucosis’s lead product candidate is SynGEM:registered:, an intranasal vaccine to prevent respiratory syncytial virus infection. Mucosis' vaccines are based on the patented and validated Mimopath:registered: technology. This technology enables a more natural immune response as well as a broad base of protection as was seen in their proof-of-concept animal and human studies of their FluGEM:registered: vaccine candidate.